Detalhe da pesquisa
1.
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Mult Scler
; 29(14): 1808-1818, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978852
2.
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Eur J Neurol
; 29(4): 1082-1090, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724638
3.
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Mult Scler
; 27(5): 695-705, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639855
4.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538713
5.
Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis.
Eur J Neurol
; 28(3): 901-909, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326677
6.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947619
7.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386427
8.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler
; 26(1): 79-90, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31397221
9.
Vitamin D3 supplementation and neurofilament light chain in multiple sclerosis.
Acta Neurol Scand
; 141(1): 77-80, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31657006
10.
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Mult Scler
; 25(13): 1728-1735, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218911
11.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
JAMA
; 321(2): 175-187, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30644981
12.
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Mult Scler
; 24(10): 1280-1287, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28731372
13.
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
Mult Scler
; 24(12): 1569-1577, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30234431
14.
Cladribine versus fingolimod, natalizumab and interferon ß for multiple sclerosis.
Mult Scler
; 24(12): 1617-1626, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857680
15.
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler
; 24(5): 642-652, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28382837
16.
Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients.
J Immunol
; 197(12): 4576-4583, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27837111
17.
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
Brain
; 140(9): 2426-2443, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29050389
18.
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Ann Neurol
; 80(1): 89-100, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27145331
19.
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 88(3): 196-203, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27683916
20.
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.
Mult Scler
; 23(10): 1346-1357, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27885062